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C BY-NC-Abstract Mannich reaction of benzotriazole (1), ethyl-4-amino benzoate (2) and formaldehyde in eth-
anol afforded 4-(1H)-benzotriazoyl methyl amino benzoate (3), which on treatment with hydrazine
hydrate results in the 4-(1H)-benzotriazoylmethyl aminobenzoyl hydrazide (4).This compoundoncon-
densation with pre-prepared various ethyl-2-substituted phenyl hydrazono-3-oxobutyrates
(6a–h), furnished 1-(4-((1H-benzo[d][1,2,3]triazol-1-yl) methyl amino) benzoyl)-3-methyl-4-(2-(4-(4-
alkylpiperazin-1-ylsulfonyl) phenyl) hydrazono)-1H-pyrazol-5(4H)-ones (7a–h). All these compounds
(7a–h) were characterized by spectral studies. The compounds showed signiﬁcant antimicrobial activity
against various bacteria and fungi.
ª 2011 King Saud University. Production and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.1. Introduction
Many pyrazoles and substituted pyrazoles derivatives are well
known for their biological and pharmacological activities (Bek-
hit et al., 2005; Pattan et al., 2009; Scheibye et al., 1982), which
exhibit an anti-inﬂammatory (Hiremith et al., 2002), fungicidal
(Dhol et al., 1975), bactericidal (Dhol et al., 1975), antipyretic
(Souza et al., 2002; McTavish, 2004), antidepressant (Palaska.com (B.P. Patel).
y. Production and hosting by
Saud University.
lsevier
ND license.et al., 2001; Rajendra et al., 2005; Ozdemir et al., 2007;
Ruhogluo et al., 2005) anticonvulsant (Ozdemir et al., 2007;
Ruhogluo et al., 2005) and protein kinase inhibitors (Abdallah,
2007). These pyrazolone derivatives were investigated as ther-
mal stabilizers for rigid PVC (Sabaa et al.,2006a,b). Arylazopy-
razoles are generally prepared by combination of aryl-azo-ethyl
actoacetate derivatives and hydrazine derivatives (Amir et al.,
2003; Bhatt et al., 2003; Patel and Singh, 2009; Kartritzky
and Rachwal, 1987; Kartritzky et al., 2005). The benzotriazole
is found as an important heterocyclic compound. It’s prime
application is as corrosion inhibitors for copper or copper al-
loys (Long and Vecek,1982; Hageolorn and Evertz, 1984). Ciba
Geigy has introduced benzotriazole derivative under the trade
name Trinvin-P (Ratway, 1981). It is applied as an UV light ab-
sorber for stabilizing plastics and other organic materials
against discolouration determination. It is employed as photo-
graphic emulsion stabilizer (Ullman’s, 1984). In the peptide
synthesis, it acts in the form of an active ester (Hadson et al.,
1990). The area in which the merged molecule like aryl azo pyr-









308 P.J. Shah et al.biological properties of both these compounds. The present
authors did initial work as this aspect (Patel et al., 2010). In
continuation with this work, the present paper comprises the
synthesis and characterization of azopyrazole- benzotriazole





































All chemicals used were of laboratory grade. Ethyl-4-amino
benzoate and Benzotriazole were prepared by reported method
(Vogel, 1978). The sulfonamide derivatives 5a–h were prepared
by reported method (Patel et al., 2003).
2.2. Measurement
Melting points were determined in open capillary tubes and
were uncorrected. IR spectra were recorded in KBr pellets
on a Nicolet 760D spectrometer. 1H NMR and 13C NMR
spectra were recorded in DMSO with TMS as internal stan-
dard on a Bruker spectrometer at 400 MHz and 100 MHz
respectively. LC–MS of selected samples was taken on a LC–
MSD-Trap-SL_01046 instrument.
2.3. Synthesis of 4-(1H)-benzotriazolyl methyl amino benzoate
(3)
A mixture of 1H-Benzotriazole (1) (0.02 mol), formaldehyde
(0.02 mol) and ethyl-4-amino benzoate (2) (0.02 mol) in etha-
nol (50 ml) was heated under reﬂux for 4 h. Subsequently, eth-
anol was distilled off and the pasty mass obtained, which was
triturated with petroleum ether (40–60 C). The solid 4-(1H)-
benzotriazolyl methyl amino benzoate (3) was isolated and
dried.
Yield 68%, m.p. 146–147 C. IR [m, cm1, KBr]: 3034–3086
(C–H aromatic), 2965 (CH2), 2910–2890 (C–H), 1725 (C‚O
of ester), 1456 (C–H), 1255–1197 (C–N). 1H NMR [400 MHz,
d, ppm, DMSO-d6]: 8.20–6.56 (8H, m, Ar-H, J= 8.2, 7.8, 1.1,
1.0, 0.09, 0.1 Hz), 5.71 (2H, s, CH2), 3.2 (1H, s, NH), 4.32
(2H, q, –O–CH2), 1.32 (3H, t, –CH3).
13C NMR [100 MHz, d,
ppm,DMSO]: 170.4 (CO), 145.6, 132.9, 127.3, 120.6, 114.3 (ben-
zotriazole Ar-C), 149.1, 130.8, 118.7, 114.5 (Ar-C), 75.7 (CH2),
62.1 (CH2), 13.9 (CH3). LC–MS:m/z 305 (M
+). Anal. Calcd for
C16H16N4O2 (296) C, 64.85; H, 5.44; N, 18.91. Found: C, 64.83;
H, 5.43; N, 18.90.
2.4. Synthesis of 4-(1H)-benzotriazolyl methyl amino benzoyl
hydrazide (4)
4-(1H)-benzotriazolyl methyl amino benzoate (3) (0.05 mol)
was reﬂuxed with hydrazine hydrate (0.05 mol) in absolute eth-
anol for 8–10 h. It was cooled and kept overnight. The solid so
obtained was ﬁltered and recrystallized from ethanol.
Yield 63%, m.p. 77–78 C. IR [m, cm1, KBr]: 3450, 1630
(NH2), 3034–3086 (C–H aromatic), 2965 (CH2), 1725 (C‚O
of ester), 1197–1255 (C–N). 1H NMR [400 MHz, d, ppm,
DMSO-d6]: 9.66 (1H, s, CONH), 8.21–6.56 (8H, m, Ar-H,
J= 8.2, 7.8, 1.1, 1.0, 0.09, 0.1 Hz), 5.7 (2H, s, CH2), 3.95
(2H, s, NH2), 3.2 (1H, s, NH).
13C NMR [100 MHz, d, ppm,
DMSO]: 170.4 (CO), 145.6, 132.9, 127.3, 120.6, 114.3 (benzo-triazole Ar-C), 149.1, 130.8, 118.7, 114.5 (Ar-C), 75.7 (CH2).
LC–MS: m/z 291 (M+). Anal. Calcd for C14H14N6O (282):
Calcd.: C, 59.56; H, 5.00; N, 29.77. Found: Calcd.: C, 59.55;
H, 4.98; N, 29.75.
2.5. General procedure for the preparation of Synthesis of ethyl-
2-substituted phenyl hydrazono-3-oxobutyrates (6a–h)
Sulphonamide derivatives (5a–h) (0.01 mol) were dissolved in a
mixture of HCl (8 ml) and water (6 ml) and cooled to 0 C in
ice bath. To it a cold aqueous solution of sodium nitrate
(0.03 mol) was added. The diazonium salt solution was ﬁltered
into a cooled solution of ethyl actoacetate (0.01 mol) and so-
dium acetate (0.12 mol) in ethanol (50 ml). The resulting solid
was washed with water and recrystallized from EtOH/MeOH.
All the compounds of this series were prepared by adopting
similar type of procedures.
2.5.1. Ethyl 2-(2-(3-(4-methylpiperazin-1-ylsulfonyl)phenyl)
hydrazono)-3-oxobutanoate (6a)
Yield 75%; m.p. 145–148 C. IR [m, cm1, KBr]: 3369 (N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1765
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1197–1255
(C–N), 1148 (C–O). 1H NMR [400 MHz, d, ppm, DMSO-
d6]: 11.62 (1H, s, NH), 7.67–6.90 (4H, s, ArH, J= 7.4, 2.5,
0.1 Hz), 4.29 (2H, q, COCH2), 3.10–2.40 (8H, t, CH2), 2.54
(3H, s, CH3), 2.35 (3H, s, COCH3), 1.34 (3H, t, CH3).
13C









R= (a) Methyl;              (b) Ethyl;   (c) Benzyl;     
     (d) Phenyl;   (e) 2,3-dichlorophenyl; (f) 3-chlorophenyl;   
     (g) 2-tetrahydrofuroyl; (h) hydroxyl ethanol 
Scheme 2
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(CH3), 48.7 (CH2), 26.9, 14.2 (CH3). LC–MS: m/z 402 (M
+).
Anal. Calcd for C17H24N4O5S (396): C, 51.50; H, 6.10; N,
14.13; S, 8.09. Found: C, 51.49; H, 6.08; N, 14.11; S, 8.08.
2.5.2. Ethyl 2-(2-(3-(4-ethylpiperazin-1-ylsulfonyl)phenyl)
hydrazono)-3-oxobutanoate (6b)
Yield 73%; m.p. 164–166 C. IR [m, cm1, KBr]: 3369 (N–H),
3034–3086 (C–H aromatic), 2920, 1465 (CH3, CH2), 1765–
1725 (C‚O), 1640–1596 (C‚N), 1255–1197 (C–N), 1148
(C–O). 1H NMR [400 MHz, d, ppm, DMSO-d6]: 11.62 (1H,
s, NH), 7.67–6.90 (4H, m, ArH, J= 7.3, 2.4, 0.1 Hz), 4.29
(2H, q, COCH2), 3.10–2.40 (8H, t, CH2), 2.43 (1H, q, CH2),
2.35 (3H, s, COCH3), 1.34–1.06 (6H, t, CH3).
13C NMR
[100 MHz, d, ppm, DMSO]: 195.4, 165.4 (CO), 143.6, 138.2,
127.9, 117.6, 114.8 (Ar-C), 61.4 (CH2), 56.6 (CH2), 49.7
(CH3), 48.7 (CH2), 26.9, 14.2, 13.6 (CH3). LC–MS: m/z
418(M+). Anal. Calcd for C18H26N4O5S (410): C, 52.67; H,




Yield 69%; m.p. 170–172 C. IR [m, cm1, KBr]: 3369(N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1765
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O). 1H NMR [400 MHz, d, ppm, DMSO-
d6]: 11.62(1H, s, NH), 7.67–6.90 (9H, m, ArH, J= 7.4, 2.5,
0.1 Hz), 4.29 (2H, q, COCH2), 3.64 (2H, s, CH2), 3.34–2.52
(8H, t, CH2), 2.35 (3H, s, COCH3), 1.34 (3H, t, CH3).
13C
NMR [100 MHz, d, ppm, DMSO]: 195.4, 165.4 (CO), 143.6,
138.8, 138.2, 128.4, 127.9, 127.4, 117.6, 114.8 (Ar-C), 64.6
(CH2), 61.4 (CH2), 56.6 (CH2), 48.7 (CH2), 26.9, 14.2 (CH3).
LC–MS: m/z 484 (M+). Anal. Calcd for C23H28N4O5S (472):
C, 58.46; H, 5.97; N, 11.86; S, 6.79. Found: C, 58.45; H,
5.96; N, 11.84; S, 6.78.
2.5.4. Ethyl 2-(2-(3-(4-phenylpiperazin-1-ylsulfonyl)phenyl)
hydrazono)-3-oxobutanoate (6d)
Yield 77%; m.p. 143–145 C. IR [m, cm1, KBr]: 3369 (N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1765
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O). 1H NMR [400 MHz, d, ppm, DMSO-
d6]: 11.62(1H, s, NH), 7.67–6.90(9H, m, ArH, J= 7.6, 2.4,
0.1 Hz), 4.29(2H, q, COCH2), 3.10–2.40(8H, t, CH2),
2.35(3H, s, COCH3), 1.34 (3H, t, CH3).
13C NMR
[100 MHz, d, ppm, DMSO]: 195.4, 165.4 (CO), 149.8, 143.6,
138.8, 138.2, 129.9, 128.4, 127.9, 127.4, 122.1, 117.6, 114.8(Ar-C), 61.4 (CH2), 56.6 (CH2), 48.7 (CH2), 26.9, 14.2
(CH3). LC–MS: m/z 476 (M
+). Anal. Calcd for C22H26N4O5S
(458): C, 57.63; H, 5.72; N, 12.22; S, 6.99. Found: C, 57.62; H,
5.70; N, 12.21; S, 6.98.
2.5.5. Ethyl-2-(2-(3-(4-(2,3-dichlorophenyl)piperazin-1-ylsulfo
nyl)phenyl)hydrazono)-3-oxo butanoate (6e)
Yield 77%; m.p. 143–145 C. IR [m, cm1, KBr]: 3369(N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1255–1197
(C–N), 1765–1725 (C‚O), 1465 (CH3, CH2), 1148 (C–O),
890–910 (C–Cl). 1H NMR [400 MHz, d, ppm, DMSO-d6]:
11.62 (1H, s, NH), 7.67–6.90 (7H, m, ArH, J= 7.5, 2.2,
0.1 Hz), 4.29 (2H, q, COCH2), 3.10–2.40 (8H, t, CH2), 2.35
(3H, s, COCH3), 1.34 (3H, t, CH3).
13C NMR [100 MHz, d,
ppm, DMSO]: 195.4, 165.4 (CO), 149.8, 143.6, 138.8, 133.5,
129.4, 127.9, 127.4, 124.1, 117.8, 117.5, 117.2, 114.8 (Ar-C),
61.4 (CH2), 56.6 (CH2), 48.7 (CH2), 26.9, 14.2 (CH3). LC–
MS: m/z 539 (M+). Anal. Calcd for C22H24Cl2N4O5S (526):
C, 50.10; H, 4.59; Cl, 13.44; N, 10.62; S, 6.08. Found: C,
50.09; H, 4.58; Cl, 13.43; N, 10.61; S, 6.07.
2.5.6. Ethyl-2-(2-(3-(4-(3-chlorophenyl)piperazin-1-ylsulfonyl)
phenyl)hydrazono)-3-oxo butanoate (6f)
Yield 73%; m.p. 133–135 C. IR [m, cm1, KBr]: 3369 (N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1765–1725
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O), 890–910 (C–Cl). 1H NMR [400 MHz, d,
ppm, DMSO-d6]: 11.62 (1H, s, NH), 7.67–6.90 (8H, m, ArH,
J= 7.5, 2.6, 0.1 Hz), 4.29 (2H, q, COCH2), 3.10–2.40 (8H, t,
CH2), 2.35 (3H, s, COCH3), 1.34 (3H, t, CH3).
13C NMR
[100 MHz, d, ppm, DMSO]: 195.4, 165.4 (CO), 149.8, 143.6,
138.8, 135.4, 131.2, 127.9, 122.1, 117.5, 117.2, 114.8, 112.6,
110.8 (Ar-C), 61.4 (CH2), 56.6 (CH2), 48.7 (CH2), 26.9, 14.2
(CH3). LC–MS: m/z 507(M
+). Anal. Calcd for
C22H25ClN4O5S (432): C, 53.60; H, 5.11; Cl, 7.19; N, 11.37;
S, 6.50. Found: C, 53.59; H, 5.10; Cl, 7.18; N, 11.36; S, 6.49.
2.5.7. Ethyl-2-(2-(3-(4-(2-tetrahydrofuroyl)piperazin-1-ylsulfo
nyl)phenyl)hydrazono)-3-oxo butanoate (6g)
Yield 78%; m.p. 149–152 C. IR [m, cm1, KBr]: 3369 (N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1765
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O). 1H NMR [400 MHz, d, ppm, DMSO-
d6]: 11.62(1H, s, NH), 7.67–6.90(4H, m, ArH, J= 7.4, 2.5,
0.1 Hz), 4.76–1.92 (tetrahydro furan ring CH2), 4.29 (2H, q,
COCH2), 3.10–2.40 (8H, t, CH2), 2.35 (3H, s, COCH3), 1.34
(3H, t, CH3).
13C NMR [100 MHz, d, ppm, DMSO]: 195.4,
168.2, 165.4 (CO), 149.8, 143.6, 127.8, 117.5, 117.2, 114.7
310 P.J. Shah et al.(Ar-C), 85.6, 67.8, 32.5, 24.4 (tetra hydro furan ring CH) 61.4,
56.6, 48.7 (CH2), 26.9, 14.2 (CH3). LC–MS: m/z 496 (M
+).
Anal. Calcd for C21H28N4O7S (480): C, 52.49; H, 5.87; N,
11.66; S, 6.67. Found: C, 52.47; H, 5.86; N, 11.65; S, 6.65.
2.5.8. Ethyl-2-(2-(3-(4-(2-hydroxyl ethanolyl)piperazin-1-
ylsulfonyl)phenyl)hydrazono)-3-oxo butanoate (6h)
Yield 76%; m.p. 138–140 C. IR [m, cm1, KBr]: 3540 (OH),
3369 (N–H), 3034–3086 (C–H aromatic), 2920 (CH3, CH2),
1765–1725 (C‚O), 1640–1596 (C‚N) 1465 (CH3, CH2),
1197–1255 (C–N), 1148 (C–O). 1H NMR [400 MHz, d, ppm,
DMSO-d6]: 11.62 (1H, s, NH), 7.67–6.90 (4H, m, ArH,
J= 7.4, 2.3, 0.1 Hz), 4.29 (2H, q, COCH2), 3.72 (1H, s,
OH), 3.10–2.40 (12H, t, CH2), 2.35 (3H, s, COCH3), 1.34
(3H, t, CH3).
13C NMR [100 MHz, d, ppm, DMSO]: 195.4,
165.4 (CO), 149.8, 143.6, 127.8, 117.5, 117.2, 114.7 (Ar-C),
61.4, 59.8, 59.4, 56.6, 48.7 (CH2), 26.9, 14.2 (CH3). LC–MS:
m/z 439 (M+). Anal. Calcd for C18H26N4O6S (426): C,
50.69; H, 6.14; N, 13.14; S, 7.52. Found: C, 50.68; H, 6.13;
N, 13.13; S, 7.50.




The compounds (6a–h) (0.002 mol) dissolved in glacial acetic
acid (20 ml), a solution of 4-(1H)-benzotriazolyl methyl amino
benzoyl hydrazide (4) (0.002 mol) in 25 ml of glacial acetic acid
was added and the mixture was reﬂuxed 10–12 h. It was then
cooled and allowed to stand overnight. The resulting solid
was ﬁltered off, dried and crystallized from methanol.
All the compounds of this series were prepared by adopting
similar type of procedures.
2.6.1. Synthesis of 1-(4-((1H-benzo[d][1,2,3]triazol-1-yl) met
hylamino)benzoyl)-3-methyl-4-(2-(4-(4-methylpiperazin-1-ylsu
lfonyl)phenyl) hydrazono)-1H-pyrazol-5(4H)-one (7a)
Yield 68%; m.p. 209–211 C. IR [m, cm–1, KBr]: 3369(N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1665
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), l255–1197 (C–
N), 1148 (C–O). 1H NMR [400 MHz, d, ppm, DMSO-d6]:
11.62, 6.97 (2H, s, NH), 7.67–6.90(12H, m, ArH, J= 8.3,
1.1, 1.0 Hz), 5.64 (2H, s, CH2), 3.10–2.40 (8H, t, CH2), 2.35–
2.28 (6H, s, CH3).
13C NMR [100 MHz, d, ppm, DMSO]:
170.1, 164.3 (CO), 151.3, 145.6, 143.6, 138.2, 132.8, 130.3,
127.7, 126.6, 117.5, 117.2, 116.8, 114.8, 113.4, 112.8 (Ar-C),
129.4 (C‚N), 59.8, 56.4, 48.7 (CH2), 46.9, 11.6 (CH3). LC–
MS: m/z 628 (M+). Anal. Calcd for C29H30N10O4S (614): C,
56.67; H, 4.92; N, 22.79; S, 5.22. Found: C, 56.66; H, 4.90;
N, 22.78; S, 5.21.
2.6.2. Synthesis of 1-(4-((1H-benzo[d][1,2,3]triazol-1-yl) met
hylamino)benzoyl)-3-methyl-4-(2-(4-(4-ethylpiperazin-1-ylsulf
onyl)phenyl) hydrazono)-1H-pyrazol-5(4H)-one (7b)
Yield 64%; m.p. 198–201 C. IR [m, cm1, KBr]: 3369 (N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1665
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O). 1H NMR [400 MHz, d, ppm, DMSO-
d6]: 11.62, 6.97(2H, s, NH), 7.67–6.90 (12H, m, ArH,
J= 8.3, 1.1, 0.09 Hz), 5.64 (2H, s, CH2), 3.10–2.40 (8H, t,CH2), 2.42 (2H, q, CH2), 2.35 (3H, s, CH3), 1.12 (3H, t, CH3).
13C NMR [100 MHz, d, ppm, DMSO]: 170.1, 164.3 (CO),
151.3, 145.6, 143.6, 138.2, 132.8, 130.3, 127.7, 126.6, 117.5,
117.2, 116.8, 114.8, 113.4, 112.8 (Ar–C), 129.4 (C‚N), 59.8,
56.4, 49.8, 48.7 (CH2), 13.5, 11.6 (CH3). LC–MS: m/z 636
(M+). Anal. Calcd for C30H32N10O4S (628): C, 57.31; H,
5.13; N, 22.28; S, 5.10. Found: C, 57.30; H, 5.12; N, 22.27;
S, 5.09.
2.6.3. Synthesis of 1-(4-((1H-benzo[d][1,2,3]triazol-1-yl)eth
ylamino)benzoyl)-3-methyl-4-(2-(4-(4-benzylpiperazin-1-yls
ulfonyl)phenyl) hydrazono)-1H-pyrazol-5(4H)-one (7c)
Yield 62%; m.p. 205–207 C. IR [m, cm1, KBr]: 3369(N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1665
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O). 1H NMR [400 MHz, d, ppm, DMSO-
d6]: 11.62, 6.97(2H, s, NH), 7.67–6.90(17H, m, ArH, J= 8.3,
1.2, 0.09 Hz), 5.64 (2H, s, CH2), 3.74(2H, s, CH2), 3.10–2.40
(8H, t, CH2), 2.35 (3H, s, CH3).
13C NMR [100 MHz, d,
ppm, DMSO]: 170.1, 164.3 (CO), 151.3, 145.6, 143.6, 138.8,
138.2, 132.8, 130.3, 128.9, 128.5, 127.7, 127.4, 126.6, 117.5,
117.2, 116.8, 114.8, 113.4, 112.8 (Ar-C), 129.4 (C‚N), 64.8,
59.8, 54.4, 48.7 (CH2), 11.6 (CH3). LC–MS: m/z 703 (M
+).
Anal. Calcd for C35H34N10O4S (690): C, 60.86; H, 4.96; N,
20.28; S, 4.64. Found: C, 60.85; H, 4.94; N, 20.27; S, 4.62.
2.6.4. Synthesis of 1-(4-((1H-benzo[d][1,2,3]triazol-1-yl)eth
ylamino)benzoyl)-3-methyl-4-(2-(4-(4-phenylpiperazin-1-ylsulf
onyl)phenyl) hydrazono)-1H-pyrazol-5(4H)-one (7d)
Yield 65%; m.p. 212–214 C. IR [m, cm1, KBr]: 3369 (N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1665
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O). 1H NMR [400 MHz, d, ppm, DMSO-
d6]: 11.62, 6.97(2H, s, NH), 7.67–6.90 (17H, m, ArH,
J= 8.3, 1.0, 0.09 Hz), 5.64 (2H, s, CH2), 3.10–2.40 (8H, t,
CH2), 2.35 (3H, s, CH3).
13C NMR [100 MHz, d, ppm,
DMSO]: 170.1, 164.3 (CO), 151.3, 149.7, 145.6, 143.6, 138.2,
132.8, 130.3, 129.8, 127.7, 126.6, 122.3, 117.5, 114.6, 117.2,
116.8, 114.8, 113.4, 112.8 (Ar-C), 129.4 (C‚N), 59.8, 54.4,
48.7 (CH2), 11.6 (CH3). LC–MS: m/z 689 (M
+). Anal. Calcd
for C34H32N10O4S (676): C, 60.34; H, 4.77; N, 20.70; S, 4.74.
Found: C, 60.32; H, 4.73; N, 20.69; S, 4.73.




Yield 61%; m.p. 203–205 C. IR [m, cm1, KBr]: 3369(N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1665
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O), 890–910 (C–Cl). 1H NMR [400 MHz, d,
ppm, DMSO-d6]: 11.62, 6.97 (2H, s, NH), 7.67–6.90 (15H,
m, ArH, J= 8.4, 1.2, 0.09 Hz), 5.64(2H, s, CH2), 3.10–
2.40(8H, t, CH2), 2.35 (3H, s, CH3).
13C NMR [100 MHz, d,
ppm, DMSO]: 170.1, 164.3 (CO), 151.3, 150.2, 145.6, 143.6,
138.2, 133.5, 132.8, 130.3, 129.3, 127.7, 127.6, 124.3, 117.8,
114.6, 117.2, 116.8, 114.8, 113.4, 112.8 (Ar-C), 129.4 (C‚N),
59.8, 54.4, 48.7 (CH2), 11.6 (CH3). LC–MS: m/z 756 (M
+).
Anal. Calcd for C34H30Cl2N10O4S (744): C, 54.77; H, 4.06;
Cl, 9.51; N, 18.78; S, 4.30. Found: C, 54.75; H, 4.04; Cl,
9.50; N, 18.76; S, 4.28.




Yield 64%; m.p. 202–203 C. IR [m, cm1, KBr]: 3369(N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1665
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O), 890–910 (C–Cl). 1H NMR [400 MHz, d,
ppm, DMSO-d6]: 11.62, 6.97(2H, s, NH), 7.67–6.90 (16H, m,
ArH, J= 8.2, 1.3, 1.0 Hz), 5.64 (2H, s, CH2), 3.10–2.40(8H,
t, CH2), 2.35 (3H, s, CH3).
13C NMR [100 MHz, d, ppm,
DMSO]: 170.1, 164.3 (CO), 151.3, 150.8, 145.6, 143.6, 138.2,
133.5, 132.8, 130.8, 129.3, 129.3, 127.8, 127.6, 124.9, 123.8,
117.8, 114.6, 117.2, 116.8, 114.8, 113.4, 112.8 (Ar-C), 129.4
(C‚N), 59.8, 54.4, 48.7 (CH2), 11.6 (CH3). LC–MS: m/z
722(M+). Anal. Calcd for C34H31Cl1N10O4S (710): C, 57.42;
H, 4.39; Cl, 4.99; N, 19.69; S, 4.51. Found: C, 57.41; H,
4.38; Cl, 4.97; N, 19.68; S, 4.50.




Yield 62%; m.p. 214–216 C. IR [m, cm1, KBr]: 3369(N–H),
3034–3086 (C–H aromatic), 2920 (CH3, CH2), 1725–1665
(C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2), 1255–1197
(C–N), 1148 (C–O), 890–910 (C–Cl). 1H NMR [400 MHz, d,
ppm, DMSO-d6]: 11.62, 6.97(2H, s, NH), 7.67–6.90 (12H, m,
ArH, J= 8.1, 1.0 Hz), 5.64(2H, s, CH2), 4.76–1.92(tetrahydro
furan ring CH2), 3.74(2H, s, CH2), 3.10–2.40 (8H, t, CH2),
2.35(3H, s, CH3).
13C NMR [100 MHz, d, ppm, DMSO]:
170.1, 168.2, 164.3 (CO), 151.3, 145.6, 143.6, 138.2, 132.8,
130.3, 127.7, 117.5, 117.2, 116.8, 114.8, 113.4, 112.8 (Ar-C),
129.4 (C‚N), 84.8, 68.2, 59.8, 56.4, 48.7, 32.5, 25.4 (CH2),
11.6 (CH3). LC–MS: m/z 722 (M
+). Anal. Calcd for
C33H34N10O6S (710): C, 56.72; H, 4.90; N, 20.05; S, 4.59.
Found: C, 56.71; H, 4.88; N, 19.99; S, 4.58.




Yield 66%; m.p. 201–203 C. IR [m, cm1, KBr]: 3540(OH),
3369(N–H), 3034–3086 (C–H aromatic), 2920 (CH3, CH2),
1725–1665 (C‚O), 1640–1596 (C‚N), 1465 (CH3, CH2),
1197–1255 (C–N), 1148 (C–O), 1H NMR [400 MHz, d, ppm,
DMSO-d6]: 11.62, 6.97(2H, s, NH), 7.67–6.90 (12H, m, ArH,
J= 8.2, 1.1, 1.0 Hz), 5.64(2H, s, CH2), 3.67 (1H, s, OH)
3.48–2.40 (12H, t, CH2), 2.35 (3H, s, CH3).
13C NMR
[100 MHz, d, ppm, DMSO]: 170.1, 164.3 (CO), 151.3, 145.6,
143.6, 138.2, 132.8, 130.3, 127.7, 126.6, 117.5, 117.2,
116.8114.8, 113.4, 112.8 (Ar-C), 129.4 (C‚N), 59.8, 59.6,
59.34, 56.4, 48.7 (CH2), 11.6 (CH3). LC–MS: m/z 662(M
+).
Anal. Calcd for C30H32N10O5S (644): C, 55.89; H, 5.00; N,
21.73; S, 4.97. Found: C, 55.87; H, 4.99; N, 21.72; S, 4.96.
3. Results and discussion
3.1. Chemistry
The compound 4 (hydrazide) has been synthesized successfully
as the Mannich reaction reported previously (Amir et al., 2003;Bhatt et al., 2003; and Singh, 2009; Kartritzky and Rachwal,
1987; Kartritzky et al., 2005). The synthesis of 5a–h has been
performed based on the method reported (Patel et al., 2003).
From these compounds the novel compounds 6a–h has been
synthesized. The compounds 6a–h reacted with 4 to give the
corresponding compounds 7a–h. All the compounds were
conﬁrmed on the basis of the elemental analysis and spectro-
scopic investigation. IR spectrum of 4 revealed characteristic
bands at 3450, 1630 (NH2) and conﬁrmatory by
1H NMR d
3.95 (2H, s, NH2). Further, IR spectroscopic investingation
of 6a–h reveals bands at 1640–1596 (C‚N) and 1H NMR d
11.62 (1H, s, NH).
IR spectra of compounds 7a–h shows 3369 (N–H), 1640–
1596 (C‚N), 1255–1197 (C–N) and 1H NMR 11.62 (1H, s,
NH). The examination of these data reveals that the IR band
and 1H NMR signals are appropriate to the corresponding
structure of compound.
The ﬁnal structure of all compounds was conﬁrmed by 13C
NMR and LC–MS data, i.e., The compounds 7a show the
molecular ion peak m/z 628 gives the molecular weight of 7a,
i.e., 614. All these facts conﬁrm the structures 7a–h.
3.2. Biological screening
3.2.1. Antibacterial activities
Antibacterial activities of all the compounds were studied
against Gram–positive Bacteria (Bacilus subtilis and Staphyllo-
coccus aureus) and Gram-negative Bacteria (E. coil, Salmonella
typhi and Klebsiella promioe) at a concentration of 50 lg/ml by
Agar cup plate method. Methanol system was used as control
in this method. Under similar condition using sulphonamide as
a standard for comparison carried out the control experiment.
The area of inhibition of zone was measured in mm. Com-
pound 7c was found more active against the above microbes.
Other compounds were found more active against the above
microbes. The antibacterial activities all compounds are shown
in Table 1.
3.2.2. Antifungal activity
The fungicidal activity of all the compounds was studied at
1000 ppm concentration in vitro. Plant pathogenic organisms
are listed in Table 2. The antifungal activities of all the samples
were measured by cup plate method (Baily and Scott, 1966;
Banty, 1976; Simoncini et al., 1968). Each of the plant patho-
genic strains on potato dextrose agar (PDA) medium. Such a
PDA medium contained potato 200 g, dextrose 20 g, agar
20 g and water 1 l. Five days old cultures were employed.
The compounds to be tested were suspended (1000 ppm) in a
PDA medium and autoclaved at 120 C for 15 min, at
15 atm pressure. These medium were poured into sterile Petri
plate and the organisms were inoculated after cooling the Petri
plate. The percentage inhabitation for fungi was calculated
after ﬁve days using the formula given below.
Percentage of inhibition ¼ 100ðX YÞ=X
where X is the area of colony in control plate and Y the area of
colony in test plate.
The fungicidal activity all compounds are shown in Table 2.
The antifungal activity of all the compounds measured for
various plant pathogens. Inspection of the result shown in
Table 2 indicates that all compounds are good toxic for fungi.
Table 1 Antibacterial activity of 1-(4-((1H-benzo[d][1,2,3]triazol-1-yl)methyl amino) benzoyl)-3-methyl-4-(2-(4-(4-alkylpiperazin-1-
ylsulfonyl)phenyl)hydrazono)-1H-pyrazol-5(4H)-ones (7a–h).
Compounds Zone of Inhibition (mm) (activity index)std
Gram +ve Gram –ve
Bacillus Subtilis Staphylococcus Aureus Kllebsiella promioe Salmonella typhl E. coil
7a 53(0.62) 46(0.83) 66(0.80) 61(0.88) 67(0.93)
7b 46(054) 50(0.90) 75(0.91) 63(0.91) 65(0.90)
7c 80(0.94) 46(0.83) 76(0.92) 64(0.92) 62(0.86)
7d 81(0.95) 49(0.89) 74(0.90) 61(0.88) 67(0.93)
7e 84(0.98) 54(0.98) 80(0.97) 67(0.97) 70(0.97)
7f 82(0.96) 52(0.94) 78(0.95) 65(0.94) 69(0.95)
7g 78(0.91) 49(0.89) 74(0.90) 60(0.86) 66(0.91)
7h 80(0.94) 48(0.87) 76(0.92) 63(0.91) 64(0.88)
Sulphonamide 85 55 82 69 72
(Activity index)std = zone of inhibition of the sample/zone of inhibition of the standard.
Table 2 Antifungal activity of 1-(4-((1H-benzo[d][1,2,3]triazol-1-yl)methyl amino) benzoyl)-3-methyl-4-(2-(4-(4-alkylpiperazin-1-
ylsulfonyl)phenyl)hydrazono)-1H-pyrazol-5(4H)-ones (7a–h).
Zone of inhibition at 1000 ppm (%)
Compound no. Penicillium Expansum Botrydepladia Thiobromine Nigrosspora Sp. Trichothesium Sp. Rhizopus Nigricuns
7a 75 65 73 54 48
7b 66 72 66 56 66
7c 62 73 65 54 65
7d 64 68 65 61 60
7e 78 76 77 66 64
7f 76 74 76 64 63
7g 64 73 65 54 60
7h 61 70 65 52 63
312 P.J. Shah et al.These compounds almost inhibit the fungi about 60%. Hence
produced compounds can be employed as garden fungicides.
Further work in the direction is in progress.4. Conclusion
The present study reports the synthesis of novel heterocyclic
pyrazolinone from the corresponding precursors ethyl-2-
substituted phenyl hydrazono-3-oxobutyrates (6a–h) and 4-
(1H)-benzotriazolyl methyl amino benzoyl hydrazide (4). The
antimicrobial activity of 1-(4-((1H-benzo[d][1,2,3]triazol-1-yl)-
methyl amino)benzoyl)-3-methyl-4-(2-(4-(4-alkyl piperazin-1-
yl sulfonyl)phenyl) hydrazono)-1H-pyrazol-5(4H)-ones (7a–h)
was carried out against some strain bacteria. The results show
that the synthesized compounds were toxic against the bacte-
ria. The investigation of antibacterial screening reveals that
the compounds 4e and 4f have exhibited good antibacterial
activity comparable to the standard drugs, while compounds
4e and 4f display better antifungal activity.References
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